AirFluSal Forspiro Launched in Portugal & Ireland

Vectura Group has confirmed that its partner Sandoz, has announced the launch of AirFluSal Forspiro, an innovative inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD), in Portugal and Ireland.

AirFluSal Forspiro, which was first approved in Denmark, has now been launched in a total of a dozen European countries, as well as South Korea and Mexico. It has been approved in more than two dozen countries and our partner confirms that the planned global roll-out continues apace on a market-by-market basis, in line with local regulatory requirements.

AirFluSal Forspiro offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative new device. The product's safety, efficacy and equivalence have been proven in multiple clinical trials.

Vectura initially developed the VR315 product and created the design of the innovative inhaler, before licensing the asset to Sandoz in 2006.  It was subsequently developed in collaboration with Vectura as AirFluSal Forspiro by Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence. The innovative and intuitive-to-use design of the inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.